Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Core Consumer Healthcare LLC currently manages 1 pending office action. This activity is focused in the Biotechnology & Pharmaceuticals technology area. With 1 pending office action, the company's current patent prosecution efforts are concentrated on a specific matter rather than a broad array of simultaneous filings.
The examination is conducted by 1 distinct examiner who operates within 1 distinct art unit. HOFFMAN, SUSAN COE is the busiest examiner for this portfolio and is responsible for 1 pending office action. This 1 to 1 relationship between the examiner and the pending action centralizes the technical review within the Biotechnology & Pharmaceuticals sector.
The reliance on 1 distinct examiner within 1 distinct art unit means that the prosecution strategy is highly dependent on the specific interpretations of HOFFMAN, SUSAN COE. For a company in the Biotechnology & Pharmaceuticals field, this 1 pending office action requires a focused response to the specific requirements of the assigned official. The lack of multiple distinct examiners simplifies the administrative tracking of the portfolio but increases the impact of the decisions made by HOFFMAN, SUSAN COE.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOFFMAN, SUSAN COE | 1 | 54.2% | +25.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17884108 | ANTI-VIRAL COMPOSITIONS AND METHODS | HOFFMAN, SUSAN COE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17884108 | ANTI-VIRAL COMPOSITIONS AND METHODS | HOFFMAN, SUSAN COE | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17884108 | ANTI-VIRAL COMPOSITIONS AND METHODS | HOFFMAN, SUSAN COE | 1655 | §103§112 | Final Rejection | — | Pending | Aug 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCore Consumer Healthcare LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Susan Coe Hoffman has the most, with 1 of Core Consumer Healthcare LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
